Pharming Group N.V. (NASDAQ: PHAR) shares surged 16.77% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical company reported significant growth in revenue and profitability, beating analyst expectations and raising its full-year guidance.
The company's total revenues for Q3 2025 increased by 30% year-over-year to $97.3 million, surpassing the analyst consensus estimate of $93.43 million. Pharming reported quarterly earnings of $0.10 per share, significantly beating the analyst estimate of breakeven results. This represents a substantial improvement from the $0.02 loss per share in the same period last year.
Key highlights from the report include: - RUCONEST® revenues increased by 29% to $82.2 million - Joenja® (leniolisib) revenues grew by 35% to $15.1 million - Operating profit surged by 285% to $15.8 million - Full-year 2025 revenue guidance raised to $365-$375 million from $335-$350 million The strong performance was attributed to sustained growth in patients and prescribers for both RUCONEST® and Joenja®. The company also reported positive developments in its pipeline, including the FDA granting priority review for leniolisib in pediatric patients with APDS.
Pharming's CEO, Fabrice Chouraqui, expressed confidence in the business, citing the strong quarter and significant growth in revenue and profitability. The company's focus on rare diseases and its pipeline advancements, including potential new indications for leniolisib, have contributed to investor optimism. With the raised guidance and strong cash flow generation, Pharming appears well-positioned for continued growth in the rare disease market.
Comments